PROBLEM TO BE SOLVED: To provide a pharmaceutical for preventing or treating disorder accompanied by ocular angiogenesis and/or elevated ocular vascular permeability, which can reduce dosage of anti-VEGF medicine, lessen frequency of administration, and improve effectiveness.SOLUTION: This pharmaceutical is composed of a combination of the anti-VEGF agent and a hidantoin derivative represented by formula (I) or pharmacologically acceptable salt thereof； the anti-VEGF agent is selected from the group consisting of a VEGF ligand inhibitor (VEGF-Trap EYE is excluded), the VEGF receptor antagonist and VEGF-related nucleic acid medicines.【課題】抗ＶＥＧＦ薬の用量削減、投与回数の軽減、及び有効性の向上が可能な、眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬の提供。【解決手段】抗ＶＥＧＦ薬と、式（Ｉ）：で示されるヒダントイン誘導体又はその薬理学的に許容される塩と、の組み合わせから構成され、抗ＶＥＧＦ薬が、ＶＥＧＦ Ｌｉｇａｎｄ阻害剤（ＶＥＧＦ－Ｔｒａｐ ＥＹＥを除く）、ＶＥＧＦ受容体拮抗薬、及びＶＥＧＦに関連する核酸医薬からなる群から選択される。【選択図】図１
